Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT

Emine Goknur Isik; Duygu Has-Simsek; Oner Sanli; Yasemin Sanli; Serkan Kuyumcu

doi:10.1097/RLU.0000000000003837

Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT

Emine Goknur Isik, Duygu Has-Simsek, Oner Sanli, Yasemin Sanli, Serkan Kuyumcu

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

ABSTRACT: Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.

Original language	English (US)
Pages (from-to)	e54-e55
Journal	Clinical nuclear medicine
Volume	47
Issue number	1
DOIs	https://doi.org/10.1097/RLU.0000000000003837
State	Published - Jan 1 2022
Externally published	Yes

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000003837

Cite this

@article{0740c3f7023c406e8b0fe91978848a72,

title = "Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT",

abstract = "ABSTRACT: Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.",

author = "Isik, {Emine Goknur} and Duygu Has-Simsek and Oner Sanli and Yasemin Sanli and Serkan Kuyumcu",

year = "2022",

month = jan,

day = "1",

doi = "10.1097/RLU.0000000000003837",

language = "English (US)",

volume = "47",

pages = "e54--e55",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT

AU - Isik, Emine Goknur

AU - Has-Simsek, Duygu

AU - Sanli, Oner

AU - Sanli, Yasemin

AU - Kuyumcu, Serkan

PY - 2022/1/1

Y1 - 2022/1/1

N2 - ABSTRACT: Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.

AB - ABSTRACT: Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=85120322886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120322886&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000003837

DO - 10.1097/RLU.0000000000003837

M3 - Article

C2 - 34392294

AN - SCOPUS:85120322886

SN - 0363-9762

VL - 47

SP - e54-e55

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 1

ER -

Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this